Compare MEC & RCKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MEC | RCKT |
|---|---|---|
| Founded | 1945 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 527.1M | 239.3M |
| IPO Year | 2019 | 2014 |
| Metric | MEC | RCKT |
|---|---|---|
| Price | $12.83 | $2.29 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 14 |
| Target Price | ★ $36.80 | $8.58 |
| AVG Volume (30 Days) | 443.0K | ★ 2.2M |
| Earning Date | 11-03-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 26.37 |
| EPS | N/A | ★ 0.66 |
| Revenue | N/A | N/A |
| Revenue This Year | $16.40 | N/A |
| Revenue Next Year | $14.08 | $915.60 |
| P/E Ratio | ★ N/A | $3.50 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $12.72 | $2.17 |
| 52 Week High | $38.76 | $5.45 |
| Indicator | MEC | RCKT |
|---|---|---|
| Relative Strength Index (RSI) | 24.01 | 37.55 |
| Support Level | N/A | N/A |
| Resistance Level | $18.84 | $3.70 |
| Average True Range (ATR) | 0.81 | 0.18 |
| MACD | 0.02 | 0.01 |
| Stochastic Oscillator | 3.01 | 19.51 |
Mayville Engineering Co Inc is involved in a manufacturing partner providing a full suite of manufacturing solutions from concept to production, including design, prototyping and tooling, fabrication, aluminum extrusion, coating, assembly, and aftermarket components. Its customers operate in diverse end markets, including heavy- and medium-duty commercial vehicles, construction, powersports, agriculture, military, and other end markets. Its services comprise stamping, shearing, fiber laser cutting, forming, drilling, tapping, grinding, tube bending, machining, welding, assembly, and logistic services.
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. It has one reportable segment related to R&D and commercial readiness of its gene therapies.